Biocytogen Expands Partnership with Merck

29-Aug-2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMiceTM platform. Under the terms of the agreement, Merck will have full access to Biocytogen’s RenMiceTM platform to discover and develop fully human antibody ...

Genmab announces progress with Lundbeck collaboration

First pre-clinical milestone met in Lundbeck collaboration

19-Dec-2011 - Genmab A/S announced it had reached the first pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the first milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the ...

Genmab Announces Antibody Development Collaboration with Lundbeck

15-Oct-2010 - Genmab A/S announced an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H. Lundbeck A/S. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab’s antibody creation ...

AbCheck: Antibody Discovery Deal

First validation of technology and business approach

07-Oct-2010 - AbCheck s.r.o. announced an antibody discovery deal with Eli Lilly and Company. Under the agreement, AbCheck will use its three antibody discovery libraries to deliver high-affinity, fully human antibodies against an undisclosed number of Lilly targets. The three distinct human antibody libraries ...

Sanofi Pasteur Partners With Vivalis For The Discovery of Human Monoclonal Antibodies Against Infectious Diseases

10-Jun-2010 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced the signature with Vivalis of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious diseases. Under the terms of the agreement, ...

Galapagos receives EUREKA innovation label and OSEO funding

27-Nov-2009 - Galapagos NV announced that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO. Accordingly, the Paris-based Galapagos R&D center will receive interest free loans from OSEO worth €1.2 M over the next two ...

GENEART and MorphoSys Successfully Cooperate in HuCAL PLATINUM Project

19-Dec-2008 - GENEART and MorphoSys announced their successful cooperation in the HuCAL PLATINUM® project. The application of GENEART's proprietary sequence design software GeneOptimizer® and production of significant parts of the antibody library allowed GENEART to make a large contribution to this project, ...

MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease

Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies

28-Nov-2008 - MorphoSys AG and Galapagos NV announced the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis. The alliance spans all ...

Crucell Announces Research License Agreement with Bioceros on STAR Technology

21-May-2008 - Crucell N.V. announced a non-exclusive STAR® research license agreement with Bioceros. The license agreement with the Netherlands based company Bioceros covers the production of monoclonal antibodies. Financial details of the agreement were not disclosed. According to the company, STAR® ...

Crucell Announces STAR Research License Agreement with Toyobo Gene Analysis Co. LTD.

05-May-2008 - Crucell N.V. announced a non-exclusive STAR® research license agreement with Toyobo Gene Analysis Co. LTD. Under the agreement, Toyobo Gene Analysis will evaluate Crucell's STAR® technology for generating cell lines for the production of recombinant proteins for third-party customers. Financial ...